PHARMACOPOEIAL DISCUSSION GROUP

Q11

STERILITY REV. 1

It is understood that sign-off covers the technical content of the draft and each party will adapt it as necessary to conform to the usual presentation of the pharmacopoeia in question; such adaptation includes stipulation of the particular pharmacopoeia's reference materials and general chapters.

European Pharmacopoeia Signature Name		Date
Signature	rume	2
Cerre	LE: TEL	30.10.2007
Japanese Pharmacoj Signature	p oeia Name	Date
Diyin las for	Toshiro Nakagaki	<u>Oct 30.2007</u>
United States Pharm	•	D .
Signature	Name	Date
the state of the s	HARROLL,	30 OC 2007
Local requirements	/13 EROVET 179	

Local requirements

- In the section on « Test for sterility of the product to be examined », USP will add a paragraph on « Number of articles to be tested ».
- USP will add a requirements for testing of for pharmacy bulk packages (this includes description of media for penicillins and cephalosporins; use of alternative micro-organisms to the those indicated in Table 1; description of additional diluting and rinsing fluids for membrane filtration)
- USP will add requirements for medical devices in Table 2